Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 9CNS 5Lymphoid 4Genitourinary 4Dermatologic 4Myeloid 3Thoracic 2Sarcoma 2Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2Head & Neck 2Gynecologic 2Breast 1

Conditions

Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Cisplatin 147pembrolizumab 129Carboplatin 126Injections 108Pemetrexed 99Paclitaxel 97Gemcitabine 85Irinotecan 75Cyclophosphamide 72Nivolumab 71Docetaxel 68Bevacizumab 59Oxaliplatin 50Fluorouracil 50Capecitabine 48atezolizumab 46Leucovorin 42Etoposide 42tislelizumab 40toripalimab 36fludarabine 32Drug Therapy 32Ipilimumab 30Topotecan 29durvalumab 28Vincristine 27Specimen Handling 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ulixertinib × Other solid neoplasm × Clear all
NCT04488003 2024-06-04

Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

BioMed Valley Discoveries, Inc

Phase 2 Terminated
104 enrolled 13 charts
Other solid neoplasm

Advanced Solid Tumor

NCT01781429 2020-03-20

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

BioMed Valley Discoveries, Inc

Phase 1/2 Completed
136 enrolled 25 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡